ClinicalTrials.gg
Status unknownNCT00426920Updated Jan 25, 2007

Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler

A Phase 1 interventional study of Insulin in Diabetes Mellitus, sponsored by QDose Limited. Status unknown at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-01-25.

Sponsored by QDose Limited · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2007), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing insulin in Diabetes Mellitus — 1 open to participants now, 2 under way, none of them phase 3. Insulin · Diabetes Mellitus.

Enrollment
41st of 49
14 · median 74
Started
2007
with 4 others
Phase 1
2 of 51
none open now
Registered
12th of 51
by date

Among the 51 studies testing insulin in Diabetes Mellitus, this one is the 41st largest by enrollment of the 49 interventional ones that give a count, is one of 5 that started in 2007, is one of 2 in phase 1, and was the 12th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 51 studies testing insulin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing insulin in Diabetes Mellitus, or all of them as a file.
02

Study summary

Evaluation of the pharmacokinetics and pharmacodynamics of different doses of spray-dried recombinant human insulin powder for inhalation administered via a dry powder uinhalation device compared with subcutaneously administered regular human insulin in healthy male volunteers under the conditions of a eugycemic clamp.

Read the detailed description

Explorative, single-center, randomized, open label, 4-way crossover study to evaluate the pharmacokinetics and pharmacodynamics of different doses of spray-dried recombinant human insulin powder for inhalation administered via a dry powder uinhalation device compared with subcutaneously administered regular human insulin in healthy male volunteers under the conditions of a eugycemic clamp.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • pharmacokinetics
  • pharmacodynamics
  • inhaled
  • recombinant human insulin
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male
  • non smoking for at least 12 months
  • equal to or less than 28
  • no abnormalities
  • FVC and equal to or more than 80%
  • willing to participate and to sign form

Exclusion criteria

Exclusion Criteria:

  • positive results for insulin antibodies at screening
  • history of substance abuse or dependency within last 5 years
  • positive screening test for substance abuse
  • positive blood test for , or antibody
  • fasting blood glucose of more than 126mg/dl
  • any existing medical conditions which might interfere with absoprtion, distribution, metabolism or excretion of study medication
  • history of bronchospastic disease(asthma), tachycardia, migraine headache, hypoglycemic episodes, jaundice, liver diseases, arterial hemorrhaging, severe hypertension or hypotension, cardiac abnormality, renal disease, allergies, unresolved psychiatric illness, drug-induced myopathy or any other abnormality
  • has received medications within 21 days prior to receiving the first dose of study medication
  • has taken or used any prescription medications within 21 days prior to receiving the first dose of study medication
  • has taken or used any OTC medications,vitamins or herbal and/or nutritional supplements within 10 days days prior to receiving the first dose of study medication
  • health that may be adversely affected by procedures or medications used in the study
  • unwillingness or inability to understand or to follow required study restrictions and procedures
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants

Interventions

06

What researchers measure

Primary outcomes

  1. maximum insulin serum concentration

  2. early T50%

  3. late T50%

  4. Tmax

  5. AUC

Secondary outcomes

  1. maximum glucose infusion rate

  2. early T50%

  3. late T50%

  4. Tmax

  5. AUC

07

Study locations

1 site
  • Profil Institute for Clinical Research Incorporated
    Chula Vista, California 91911, United States
    • Marcus hompesch, MD · Contact619-427-1300
    • 24-hour emergency number · Contact619-409-1277
    • Marcus Hompesch, MD · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00426920
Lead sponsor
QDose Limited
First posted
Jan 25, 2007
Start date
Feb 2007
Last update
Jan 25, 2007

Study contacts

Marcus Hompesch, MD
Contact
619-427-1300
24-hour emergency number
Contact
619-409-1277
Marcus Hompesch, MD
principal investigator · Profil Institute for Clinical Research Incorporated
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion